ARTICLE | Clinical News
Panzem NCD 2-methoxyestradiol: Development discontinued
May 12, 2008 7:00 AM UTC
EntreMed reported in its earnings that in March it discontinued development of Panzem NCD for oncology indications because further development would “require the commitment of a disproportionate amoun...